.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
AstraZeneca
McKinsey
Baxter
Merck
Colorcon
Cipla
Johnson and Johnson
Citi

Generated: September 21, 2017

DrugPatentWatch Database Preview

Biogen Idec Company Profile

« Back to Dashboard

What is the competitive landscape for BIOGEN IDEC, and what generic alternatives to BIOGEN IDEC drugs are available?

BIOGEN IDEC has two approved drugs.

There are fifteen US patents protecting BIOGEN IDEC drugs on BIOGEN IDEC drugs in the past three years.

There are six hundred and two patent family members on BIOGEN IDEC drugs in thirty-six countries.

Summary for Applicant: Biogen Idec

Patents:15
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-001Mar 27, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-002Mar 27, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-002Mar 27, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-002Mar 27, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-001Mar 27, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-001Mar 27, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BIOGEN IDEC drugs

Drugname Dosage Strength Tradename Submissiondate
dimethyl fumarate
Delayed-releaseCapsules120 mg and 240 mg
TECFIDERA
3/27/2017

Non-Orange Book Patents for Biogen Idec

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,586,559Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences► Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
6,172,216 Antisense modulation of BCL-X expression► Subscribe
6,642,367 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
6,222,025 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
9,107,933Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III► Subscribe
7,612,110Utilization of dialkylfumarates► Subscribe
9,476,042Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences► Subscribe
7,915,310Utilization of dialkylfumarates► Subscribe
5,861,493 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Biogen Idec Drugs

Country Document Number Estimated Expiration
Austria261984► Subscribe
Israel245096► Subscribe
Australia655937► Subscribe
Serbia49995► Subscribe
Australia2002341548► Subscribe
Israel105033► Subscribe
European Patent Office1131465► Subscribe
Japan3131222► Subscribe
Austria222290► Subscribe
European Patent Office0586570► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Biogen Idec Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
487Luxembourg► SubscribePRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140203
2014 00036Denmark► SubscribePRODUCT NAME: DIMETHYL FUMARAT (DIMETHYLFUMARAT); REG. NO/DATE: EU/1/13/837/001-002 20140130
C/GB02/030United Kingdom► SubscribePRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
C/GB01/008United Kingdom► SubscribePRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026
2014024Lithuania► SubscribePRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
90038-5Sweden► SubscribePRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140203
90039-3Sweden► SubscribePRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140130
C/GB98/002United Kingdom► SubscribePRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730
2014023Lithuania► SubscribePRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
2014 00035Denmark► SubscribePRODUCT NAME: DIMETHYL FUMARAT (DIMETHYLFUMARAT); REG. NO/DATE: EU/1/13/837/001-002 20140130
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Novartis
Covington
Queensland Health
Colorcon
AstraZeneca
UBS
Argus Health
Fish and Richardson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot